other material
confidence high
sentiment positive
materiality 0.85
Terns Pharma reports positive Phase 1 data for oral GLP-1R agonist TERN-601; max placebo-adjusted weight loss 4.9%
Terns Pharmaceuticals, Inc.
- TERN-601 achieved 4.9% placebo-adjusted mean weight loss at 740 mg QD over 28 days (p<0.0001); 5.5% absolute mean loss.
- 67% of top-dose participants lost ≥5% baseline body weight; no treatment-related dose interruptions or discontinuations.
- Over 95% of AEs were mild; all GI events mild-to-moderate; no serious AEs or clinically meaningful lab/vital changes.
- Company plans to initiate Phase 2 in 2025, with optimal dose range identified and no additional dose exploration needed.
- Terns highlights distinct drug properties (low solubility, high gut permeability, low free fraction) as potential advantages over other oral GLP-1R agonists.